Entrada Therapeutics grants director 19,000 stock options
Entrada Therapeutics director Gina Chapman received a grant of stock options to buy 19,000 shares of common stock at an exercise price of $5.97 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Entrada Therapeutics director Gina Chapman received a grant of stock options to buy 19,000 shares of common stock at an exercise price of $5.97 per share. These options vest on the earlier of the one-year anniversary of June 10, 2026 or the company’s next annual meeting of stockholders and expire on June 10, 2036.
Insider Trade Summary
Grant/Award: 19,000 shares
Grant/Award
1 txn
Insider
Chapman Gina
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 19,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 19,000 contracts (Direct)
Footnotes (1)
- F1. The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders.
Key Figures
Options granted: 19,000 options
Exercise price: $5.97 per share
Underlying shares: 19,000 shares
+2 more
5 metrics
Options granted
19,000 options
Stock Option (Right to Buy) granted on June 10, 2026
Exercise price
$5.97 per share
Conversion or exercise price for underlying common stock
Underlying shares
19,000 shares
Underlying common stock for the option grant
Post-grant derivative holdings
19,000 derivative securities
Total stock options following the transaction
Option expiration
June 10, 2036
Expiration date of the stock options
Key Terms
Stock Option (Right to Buy), exercise price, derivative securities, annual meeting of stockholders
4 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "5.9700""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
derivative securities financial
"derivativeTransactionCount: 1, derivative-type records"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
annual meeting of stockholders financial
"the Issuer's next annual meeting of stockholders."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Entrada Therapeutics (TRDA) report for Gina Chapman?
Entrada Therapeutics reported that director Gina Chapman received a grant of stock options for 19,000 shares of common stock. These options give her the right to buy shares at a fixed exercise price, subject to vesting conditions and an expiration date.
How many Entrada Therapeutics (TRDA) options did Gina Chapman receive?
Gina Chapman received stock options covering 19,000 shares of Entrada Therapeutics common stock. The filing also notes that, following this award, her total stock option holdings reported in this transaction amount to 19,000 derivative securities related to common shares.
What is the exercise price of Gina Chapman’s Entrada Therapeutics (TRDA) options?
The stock options granted to Gina Chapman have an exercise price of $5.97 per share. This means she can buy Entrada Therapeutics common stock at $5.97 for each optioned share once the options vest and before they expire in 2036.
When do Gina Chapman’s Entrada Therapeutics (TRDA) options vest?
The options vest and become exercisable on the earlier of two dates: the one-year anniversary of June 10, 2026, or Entrada Therapeutics’ next annual meeting of stockholders. Vesting must occur before she can use the options to purchase common shares.
When do Gina Chapman’s Entrada Therapeutics (TRDA) options expire?
Gina Chapman’s stock options are scheduled to expire on June 10, 2036. After this expiration date, any unexercised options will no longer be usable to purchase Entrada Therapeutics common stock, even if they have already vested.
Is Gina Chapman’s Entrada Therapeutics (TRDA) option grant a market purchase or a compensation award?
The Form 4 classifies the transaction as a grant or award acquisition with a zero-dollar transaction price. This indicates the options were granted as compensation rather than bought on the open market, consistent with a director equity award.
AI-generated analysis. How Rhea-AI works. Not financial advice.
